Supernus Pharmaceuticals (SUPN) Receivables - Net (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Receivables - Net of $211.7 million for Q2 2026, up 50.29% year-over-year from $140.8 million in Q2 2025, and up 16.18% on a QoQ basis from $182.2 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Receivables - Net (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Receivables - Net for 16 years, with the latest figure at $211.7 million in Q2 2026.
- Receivables - Net for Q2 2026 came in at $211.7 million, up 50.29% year-over-year; the trailing twelve-month figure through Jun 2026 was $211.7 million (up 50.29% YoY), and the FY2025 annual result was $187.8 million, up 32.18% from the prior year.
- Receivables - Net advanced to $211.7 million in Q2 2026, from $182.2 million in the prior quarter.
- Over five years, Receivables - Net peaked at $211.7 million in Q2 2026 and troughed at $136.6 million in Q2 2023.
- A 5-year average of $157.3 million and a median of $146.7 million in 2024 frame the typical range for Receivables - Net.
- The widest annual swing landed in 2023, when Receivables - Net slipped 13.61%; it then surged 50.29% in 2026.
- A 5-year view of Receivables - Net shows it stood at $164.1 million in 2022, then slipped by 13.6% to $141.8 million in 2023, then rose by 0.22% to $142.1 million in 2024, then surged by 32.18% to $187.8 million in 2025, then grew by 12.7% to $211.7 million in 2026.
- Per Business Quant data, the three most recent Receivables - Net figures were $211.7 million in Q2 2026, $182.2 million in Q1 2026, and $187.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 211.66 Mn |
| Jun 30, 2026 | 211.66 Mn |
| Mar 31, 2026 | 182.18 Mn |
| Mar 31, 2026 | 182.18 Mn |
| Dec 31, 2025 | 187.80 Mn |
| Dec 31, 2025 | 187.80 Mn |
| Sep 30, 2025 | 171.25 Mn |
| Sep 30, 2025 | 171.25 Mn |
| Jun 30, 2025 | 140.83 Mn |
| Jun 30, 2025 | 140.83 Mn |
| Mar 31, 2025 | 145.64 Mn |
| Mar 31, 2025 | 145.64 Mn |
| Dec 31, 2024 | 142.08 Mn |
| Dec 31, 2024 | 142.08 Mn |
| Sep 30, 2024 | 145.41 Mn |
| Sep 30, 2024 | 145.41 Mn |
| Jun 30, 2024 | 152.49 Mn |
| Jun 30, 2024 | 152.49 Mn |
| Mar 31, 2024 | 147.73 Mn |
| Mar 31, 2024 | 147.73 Mn |